Norgine Enthusiastically Welcomes CHMP's Positive Opinion for Mavorixafor Approval
Norgine B.V., a leading specialty pharmaceutical company based in Europe, expressed its satisfaction following the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding mavorixafor—a treatment for WHIM syndrome. This condition, characterized by verrucae, hypogammaglobulinemia, infections, and myelokathexis due to a disfunction in the chemokine receptor CXCR4, has historically seen a lack of authorized treatment options. With the CHMP's recommendation for mavorixafor, patients suffering from WHIM now have hope for receiving this innovative therapy.
The CHMP's positive opinion is a significant regulatory milestone, paving the way for the first-ever authorized treatment targeting WHIM in Europe. Norgine has collaborated with X4 Pharmaceuticals, which developed mavorixafor that is already approved in the United States under the name XOLREMDI®. The European Commission is expected to deliver its final decision on approving mavorixafor in the second quarter of 2026.
"This positive outcome signifies a remarkable advancement for those living with the WHIM syndrome," stated Janneke van der Kamp, CEO of Norgine. "Our organization is deeply committed to innovating solutions that cater to shifting medical needs, notably in rare and specialized conditions."
The foundation of the positive CHMP opinion is the results from the pivotal Phase 3 trial known as 4WHIM, which was a global, multicenter, randomized, double-blinded, placebo-controlled study. The trial focused on the efficacy and safety of mavorixafor in 31 participants aged 12 and older diagnosed with WHIM syndrome over its 52-week duration. The results of this study underline mavorixafor's potential to significantly increase the circulation of mature neutrophils and lymphocytes, thereby addressing the underlying immune deficiencies inherent in WHIM syndrome.
Upon successful approval, Norgine will be fully responsible for the commercialization of mavorixafor in Europe, Australia, and New Zealand. The agreement with X4 Pharmaceuticals allows Norgine not only to market mavorixafor but also assures the seamless transfer of marketing authorizations in the territories outlined in the agreement. X4 will provide the required manufacturing and supply chain to Norgine.
WHIM syndrome remains a significant challenge as it is classified as an ultra-rare disease combining primary immunodeficiency with chronic neutropenia. As the condition stems from CXCR4 receptor dysfunction, the resulting complications can lead to recurrent severe infections due to low levels of neutrophils and lymphocytes in the bloodstream.
Mavorixafor acts as a selective antagonist of CXCR4, successfully blocking its interaction with CXCL12, making it a promising therapeutic option for patients. For many years, Norgine has remained committed to delivering innovative medicines, expanding their reach in essential and underserved medical areas. With a workforce of over 1,500 employees and an annual revenue of around $650 million, Norgine focuses on meeting unmet medical needs. By leveraging its capabilities in development, marketing, and manufacturing, enhanced through strategic partnerships, the company continues to shape the future of patient care one treatment at a time.
In conclusion, the positive opinion from the CHMP regarding mavorixafor heralds a new beginning for WHIM syndrome patients awaiting an effective treatment to manage their rare condition. As we await the final decision from the European Commission, the commitment from Norgine to enhance patients' lives remains unwavering.
[Note: An exceptional circumstance marketing authorization allows for approval of medicines where comprehensive data on efficacy and safety are unavailable due to the rarity of the condition or challenges in ethical data collection.]
The CHMP's positive opinion is a significant regulatory milestone, paving the way for the first-ever authorized treatment targeting WHIM in Europe. Norgine has collaborated with X4 Pharmaceuticals, which developed mavorixafor that is already approved in the United States under the name XOLREMDI®. The European Commission is expected to deliver its final decision on approving mavorixafor in the second quarter of 2026.
"This positive outcome signifies a remarkable advancement for those living with the WHIM syndrome," stated Janneke van der Kamp, CEO of Norgine. "Our organization is deeply committed to innovating solutions that cater to shifting medical needs, notably in rare and specialized conditions."
The foundation of the positive CHMP opinion is the results from the pivotal Phase 3 trial known as 4WHIM, which was a global, multicenter, randomized, double-blinded, placebo-controlled study. The trial focused on the efficacy and safety of mavorixafor in 31 participants aged 12 and older diagnosed with WHIM syndrome over its 52-week duration. The results of this study underline mavorixafor's potential to significantly increase the circulation of mature neutrophils and lymphocytes, thereby addressing the underlying immune deficiencies inherent in WHIM syndrome.
Upon successful approval, Norgine will be fully responsible for the commercialization of mavorixafor in Europe, Australia, and New Zealand. The agreement with X4 Pharmaceuticals allows Norgine not only to market mavorixafor but also assures the seamless transfer of marketing authorizations in the territories outlined in the agreement. X4 will provide the required manufacturing and supply chain to Norgine.
WHIM syndrome remains a significant challenge as it is classified as an ultra-rare disease combining primary immunodeficiency with chronic neutropenia. As the condition stems from CXCR4 receptor dysfunction, the resulting complications can lead to recurrent severe infections due to low levels of neutrophils and lymphocytes in the bloodstream.
Mavorixafor acts as a selective antagonist of CXCR4, successfully blocking its interaction with CXCL12, making it a promising therapeutic option for patients. For many years, Norgine has remained committed to delivering innovative medicines, expanding their reach in essential and underserved medical areas. With a workforce of over 1,500 employees and an annual revenue of around $650 million, Norgine focuses on meeting unmet medical needs. By leveraging its capabilities in development, marketing, and manufacturing, enhanced through strategic partnerships, the company continues to shape the future of patient care one treatment at a time.
In conclusion, the positive opinion from the CHMP regarding mavorixafor heralds a new beginning for WHIM syndrome patients awaiting an effective treatment to manage their rare condition. As we await the final decision from the European Commission, the commitment from Norgine to enhance patients' lives remains unwavering.
[Note: An exceptional circumstance marketing authorization allows for approval of medicines where comprehensive data on efficacy and safety are unavailable due to the rarity of the condition or challenges in ethical data collection.]
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.